UA120364C2 - Кон'югат антитіла до igf-1r з лікарським засобом - Google Patents

Кон'югат антитіла до igf-1r з лікарським засобом Download PDF

Info

Publication number
UA120364C2
UA120364C2 UAA201611833A UAA201611833A UA120364C2 UA 120364 C2 UA120364 C2 UA 120364C2 UA A201611833 A UAA201611833 A UA A201611833A UA A201611833 A UAA201611833 A UA A201611833A UA 120364 C2 UA120364 C2 UA 120364C2
Authority
UA
Ukraine
Prior art keywords
sequence
antibody
zeo
light chain
heavy chain
Prior art date
Application number
UAA201611833A
Other languages
English (en)
Ukrainian (uk)
Inventor
Айан Рілатт
Айан РИЛАТТ
Мішель Перес
Мишель ПЕРЕС
Ліліан Гьотш
Лилиан ГЁТШ
Маттьйо Брусса
Шарлотт БО-ЛАРВОР
Жан-Франсуа Хьов
Тьєррі Шампьйон
Тьерри Шампьйон
Ален РОБЕР
Original Assignee
Пьєр Фабр Медікамент
Пьер Фабр Медикамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьєр Фабр Медікамент, Пьер Фабр Медикамент filed Critical Пьєр Фабр Медікамент
Publication of UA120364C2 publication Critical patent/UA120364C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201611833A 2014-04-25 2015-04-27 Кон'югат антитіла до igf-1r з лікарським засобом UA120364C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305620 2014-04-25
PCT/EP2015/059045 WO2015162291A1 (en) 2014-04-25 2015-04-27 Igf-1r antibody-drug-conjugate and its use for the treatment of cancer

Publications (1)

Publication Number Publication Date
UA120364C2 true UA120364C2 (uk) 2019-11-25

Family

ID=50630736

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201611833A UA120364C2 (uk) 2014-04-25 2015-04-27 Кон'югат антитіла до igf-1r з лікарським засобом

Country Status (27)

Country Link
US (2) US10633448B2 (enExample)
EP (2) EP3498301A1 (enExample)
JP (1) JP6258523B2 (enExample)
KR (1) KR101795984B1 (enExample)
CN (1) CN106456800B (enExample)
AU (1) AU2015250759B2 (enExample)
BR (1) BR112016024619A2 (enExample)
CA (1) CA2946469C (enExample)
CY (1) CY1121783T1 (enExample)
DK (1) DK3134124T3 (enExample)
ES (1) ES2727103T3 (enExample)
HR (1) HRP20190888T8 (enExample)
HU (1) HUE044862T2 (enExample)
IL (1) IL248455B (enExample)
LT (1) LT3134124T (enExample)
MA (2) MA47811A (enExample)
MX (1) MX372912B (enExample)
MY (1) MY186711A (enExample)
PL (1) PL3134124T3 (enExample)
PT (1) PT3134124T (enExample)
RS (1) RS58742B1 (enExample)
RU (1) RU2692563C2 (enExample)
SA (1) SA516380120B1 (enExample)
SI (1) SI3134124T1 (enExample)
TN (1) TN2016000472A1 (enExample)
UA (1) UA120364C2 (enExample)
WO (1) WO2015162291A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120364C2 (uk) * 2014-04-25 2019-11-25 Пьєр Фабр Медікамент Кон'югат антитіла до igf-1r з лікарським засобом
RU2728568C2 (ru) * 2015-10-26 2020-07-30 Пьер Фабр Медикамент Композиция для лечения рака, экспрессирующего igf-1r
EP3427055A1 (en) 2016-03-07 2019-01-16 Pierre Fabre Medicament A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
BR112021005655A2 (pt) 2018-09-27 2021-06-29 Pierre Fabre Medicament ligantes à base de sulfomaleimida e conjugados correspondentes
CN111327570B (zh) 2018-12-14 2021-09-17 北京京东尚科信息技术有限公司 验证方法、装置和计算机可读存储介质
EP3735991A1 (fr) 2019-05-06 2020-11-11 Pierre Fabre Medicament Adc pour un traitement concomitant ou postérieur au docétaxel
MY210304A (en) * 2020-04-02 2025-09-10 Mersana Therapeutics Inc Antibody drug conjugates comprising sting agonists
EP3909612A1 (en) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
CN118059229A (zh) * 2020-10-14 2024-05-24 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
EP4536280A2 (en) * 2022-06-10 2025-04-16 Acelyrin, Inc. Anti-igf-1r antibody compositions
EP4353220A1 (en) 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
WO2024180233A1 (en) 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts A therapeutic hpv vaccine based on validated target epitopes
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2024249596A2 (en) * 2023-05-31 2024-12-05 Lirum Therapeutics, Inc. Methods for treating igf-1r-related cancers with an insulin-like growth factor 1 receptor ligand conjugated to a cytotoxic agent
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69434136T2 (de) 1993-10-01 2005-12-01 Teikoku Hormone Mfg. Co., Ltd. Dolastatin-derivate
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JP5290756B2 (ja) 2005-09-26 2013-09-18 メダレックス インコーポレイテッド 抗体−薬剤コンジュゲート及びその使用
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
AR065803A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
DK2276509T3 (en) 2008-04-11 2016-09-19 Seattle Genetics Inc DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
AU2010229192A1 (en) 2009-03-06 2011-09-29 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
WO2010146059A2 (en) * 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US20110256157A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
JP5791707B2 (ja) 2010-06-10 2015-10-07 シアトル ジェネティックス， インコーポレイテッド 新規アウリスタチン誘導体およびその使用
ES2553874T3 (es) 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
ES3004351T3 (en) * 2010-10-22 2025-03-12 Seagen Inc Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
ES2543888T3 (es) 2011-03-16 2015-08-25 Seattle Genetics, Inc. N-carboxialquil-auristatinas y su utilización
US9150644B2 (en) * 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9796754B2 (en) 2011-05-27 2017-10-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
ES2898854T3 (es) 2011-05-27 2022-03-09 Ambrx Inc Composiciones que contienen, métodos que implican, y usos de derivados de dolastatina enlazados con aminoácidos no naturales
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2858676B1 (en) 2012-06-07 2019-03-13 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
KR102190832B1 (ko) 2012-06-19 2020-12-15 암브룩스, 인코포레이티드 항cd70 항체 약물 컨쥬게이트
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
EP2885321A4 (en) 2012-08-14 2016-03-30 Angiochem Inc CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN
EP2934596A1 (en) 2012-12-21 2015-10-28 Glykos Finland Oy Linker-payload molecule conjugates
FR3005051A1 (fr) 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
PL3134125T3 (pl) * 2014-04-25 2020-04-30 Pierre Fabre Médicament Koniugat przeciwciało-lek i jego zastosowanie do leczenia raka
JP6835591B2 (ja) * 2014-04-25 2021-02-24 ピエール、ファーブル、メディカマン Ｉｇｆ−１ｒ抗体および癌処置のためのアドレッシングビヒクルとしてのその使用
UA120364C2 (uk) * 2014-04-25 2019-11-25 Пьєр Фабр Медікамент Кон'югат антитіла до igf-1r з лікарським засобом
RU2728568C2 (ru) * 2015-10-26 2020-07-30 Пьер Фабр Медикамент Композиция для лечения рака, экспрессирующего igf-1r

Also Published As

Publication number Publication date
RU2016145444A (ru) 2018-05-28
HRP20190888T8 (hr) 2019-10-04
ES2727103T8 (es) 2020-03-02
CY1121783T1 (el) 2020-07-31
RU2692563C2 (ru) 2019-06-25
US20200270352A1 (en) 2020-08-27
US11661457B2 (en) 2023-05-30
CA2946469C (en) 2019-10-29
KR101795984B1 (ko) 2017-11-10
SA516380120B1 (ar) 2019-02-27
SI3134124T1 (sl) 2019-06-28
EP3134124A1 (en) 2017-03-01
MA39909B1 (fr) 2019-05-31
LT3134124T (lt) 2019-05-27
IL248455A0 (en) 2016-11-30
US20170043031A1 (en) 2017-02-16
CN106456800A (zh) 2017-02-22
JP2017513900A (ja) 2017-06-01
KR20160146817A (ko) 2016-12-21
JP6258523B2 (ja) 2018-01-10
HUE044862T2 (hu) 2019-11-28
MX2016013704A (es) 2017-03-31
ES2727103T3 (es) 2019-10-14
US10633448B2 (en) 2020-04-28
MX372912B (es) 2020-04-27
CN106456800B (zh) 2018-05-01
EP3134124B1 (en) 2019-02-20
MA39909A (fr) 2017-03-01
BR112016024619A2 (pt) 2017-10-10
AU2015250759A1 (en) 2016-11-10
PL3134124T3 (pl) 2019-09-30
DK3134124T3 (da) 2019-05-06
CA2946469A1 (en) 2015-10-29
MA47811A (fr) 2019-06-19
EP3498301A1 (en) 2019-06-19
PT3134124T (pt) 2019-06-03
WO2015162291A1 (en) 2015-10-29
AU2015250759B2 (en) 2017-11-30
RU2016145444A3 (enExample) 2018-11-22
HRP20190888T1 (hr) 2019-07-12
RS58742B1 (sr) 2019-06-28
TN2016000472A1 (en) 2018-04-04
MY186711A (en) 2021-08-12
IL248455B (en) 2020-01-30

Similar Documents

Publication Publication Date Title
UA120364C2 (uk) Кон'югат антитіла до igf-1r з лікарським засобом
EP3830089B1 (en) 2h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists and methods and uses therefor
US11219693B2 (en) Antibody-drug-conjugate and its use for the treatment of cancer
US11806404B2 (en) Site specific homogeneous with KSP inhibitors
ES2841249T3 (es) Anticuerpo IGF-1R y su utilización como un vehículo de direccionamiento para el tratamiento del cáncer
AU2022393856B2 (en) Exatecan derivatives, linker-payloads, and conjugates and thereof
AU2022259796A1 (en) Antibody drug conjugates comprising STING agonists
TWI609887B (zh) 新穎的抗原結合蛋白及其作爲治療癌症之定址產物的用途
UA125577C2 (uk) Антигензв'язуюча молекула, які містить тримерний ліганд сімейства tnf
UA119570C2 (uk) Анти-ctla4 моноклональне антитіло або його антигензв'язувальний фрагмент, фармацевтична композиція і їх застосування
CN115515644A (zh) 一种抗体-药物偶联物，其制备方法及应用
CN107001415A (zh) 细胞毒性和抗有丝分裂化合物、及其使用方法
US20250222128A1 (en) Antibody drug-conjugates targeting c-met and methods of use thereof
US20250282786A1 (en) Tricyclic TLR7 Agonists and Uses Thereof
HK1229230B (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
HK1229230A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer